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0959-8049/ª 2017 Elsevier Ltd. All righAbstract Aim: We aimed to assess the overall cancer risk among contemporary menopausal
hormone therapy (MHT) users in Sweden and the risk for different cancer types.
Methods: A nationwide Swedish population-based cohort study including all 290,186 women
aged  40 years having used systemic MHT during the study period (July 2005 and December
2012), compared with the Swedish female background population. MHT ever-use (all MHT,
oestrogen-only MHT [E-MHT] and oestrogen plus progestin MHT [EP-MHT]) was based on
the nationwide Prescribed Drug Registry. Cancer diagnoses were grouped into 16 different
anatomical locations, for which standardised incidence ratios (SIRs) and 95% confidence in-
tervals (CIs) were calculated.
Results: The SIR of any cancer was 1.09 (95% CI: 1.07e1.11) following ever MHT, 1.04 (95%
CI: 1.01e1.06) for E-MHT and 1.14 (95% CI: 1.12e1.17) for EP-MHT. The highest SIR was
found for EP-MHT among users aged 70 years (SIR Z 1.33, 95% CI: 1.26e1.40). The risk
for invasive breast, endometrial or ovarian cancer combined was increased for any MHT
(SIR Z 1.31, 95% CI: 1.28e1.34). The risk of invasive breast cancer was increased following




J. Simin et al. / European Journal of Cancer 84 (2017) 60e68 61combined was decreased (SIR Z 0.90, 95% CI: 0.86e0.94), particularly the oesophagus
(SIR Z 0.81, 95% CI: 0.64e1.00), liver (SIR Z 0.81, 95% CI: 0.65e0.99) and colon
(SIR Z 0.90, 95% CI: 0.84e0.95).
Conclusions: MHT, notably EP-MHT, was associated with a limited increase in overall cancer
risk. The increased risk of female reproductive organ cancers was almost balanced by a
decreased risk of gastrointestinal cancers.
ª 2017 Elsevier Ltd. All rights reserved.1. Introduction
Menopausal hormone therapy (MHT) became available
approximately 60 years ago. In Sweden, oral oestrogen-
only MHT (E-MHT) was first licenced in 1956 (conju-
gated oestrogens), and the first oral combination
with progestin (EP-MHT) in 1976 (levonorgestrel/
oestradiol) [1]. Towards the end of the 1990s, Sweden
was among the top consumers of MHT in Europe [2],
with approximately 32% users [3,4]. Yet, global MHT
use has declined substantially over the past few decades,
following studies showing an increased risk of some
cancer types and cardiovascular events [5e7]. In the
United States, the number of prescriptions of E-MHT
and EP-MHT has dropped as much as 80% following
the release of Women’s Health Initiative trial results in
2002 [5,8]. In Sweden, the use of MHT has dropped 30%
to approximately 7% in 2010 [2,9].
Meta-analyses indicate that MHT is associated with
an increased risk of breast and possibly ovarian can-
cer [10,11]. Current evidence associates E-MHT with an
increased risk of endometrial cancer, but it is less clear if
combined EP-MHT can eliminate this excess risk [12]. A
reduced risk has been indicated for some gastrointestinal
cancers [13e18], yet for other cancer types the evidence
is inconsistent [19e23]. Most studies have examined
only one cancer type and grouped different MHT regi-
mens together, sometimes also including non-systemic
MHT. Moreover, there has been a great variation in
the definition of MHT use and in the age of the study
populations across studies [10,24].
Whilst detailed studies of individual cancer sites are
crucial for causal inference, data on the net effect of
MHT on total cancer risk are relevant for counselling
and management of women with menopausal related
symptoms [7,8]. To our knowledge, population-based
studies assessing the overall risk of cancer in users of
contemporary formulations of systemic MHT are non-
existent. With the aim to cover this gap of knowledge,
we used data from the nationwide registers of dispensed
drugs and incident cancers in Sweden.
2. Methods
This study followed an a priori defined study protocol
and was based on a large, nationwide cohort, whichhas been described in detail elsewhere [13,18]. All
290,186 Swedish women aged  40 years at first
recorded prescription (index date) who received 1
dispensed prescription of systemic MHT between 1st
July 2005 and 31st December 2012, according to the
Swedish Prescribed Drug Registry were included. This
registry covers all prescribed and dispensed drugs
for Swedish residents since July 2005 and was used
to extract Anatomical Therapeutic Chemical (ATC)
Classification codes, prescription and dispense dates
[25]. The Cancer Registry (initiated in 1958, >96%
complete) was used to obtain information on date and
anatomical location of all newly diagnosed can-
cers [26]. The Swedish Causes of Death Registry
(initiated in 1952, 100% complete) was used to retrieve
the date of death [27]. Women with a history of any
malignancy (apart from non-melanoma skin cancer)
were excluded. MHT ever-users were compared with
the entire Swedish source population (z2.5 million
women). Data on the total background population (by
age, sex and calendar period) were retrieved from the
Swedish Registry of the Total Population and Cancer
Registry. The Stockholm Regional Ethical Review
Board approved the study (2014/1291-31/4), without
need for informed consent.2.1. Exposure
Ever-use of systemic (oral or transdermal) MHT was
defined according to relevant medication codes in the
ATC system: oestrogens (G03C), progestins (G03D if
combined with G03C) and oestrogens plus progestins
(G03F; subdivided to continuous [G03FA] and sequential
[G03FB] combinations) and categorised as E-MHT
(oestrogen only) or EP-MHT (oestrogen users with 1
prescription of progestin during the study period).
For users of G03F combinations, >99% received oes-
tradiol. For subgroups of E-MHT (oestradiol, oestriol or
tibolone) and EP-MHT (continuously or sequentially
administered progestin; progesterone- or testosterone-
derived progestins), those receiving different MHT types
or regimens were excluded. We used the World Health
Organisation ‘daily-defined dose’ per package to estimate
the duration, taking into account the potency and pre-
scribed quantities of the drug.
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Primary outcome was the first newly diagnosed cancer,
defined by the International Classification of
Disease 10th edition, grouped into 16 anatomical loca-
tions (eTable 1), grouped into three larger groups of
cancer: ‘reproductive organ cancers’ (invasive breast,
endometrial and ovarian cancer), ‘gastrointestinal can-
cers’ (oesophageal, gastric, pancreatic, gallbladder, bile
ducts, liver, colon and rectal cancer) and ‘other cancers’
among the 10 most common non-haematological ma-
lignancies globally or in Sweden (lung cancer, malignant
melanoma, central nervous system tumours, kidney and
thyroid cancer) [28,29].2.3. Statistical analysis
Standardised incidence ratios (SIRs) with 95% confi-
dence intervals (CIs) were calculated to estimate the
relative risk of cancer. The observed cancer incidence
among MHT ever-users was divided by the expected
incidence based on the Swedish female population of the
same age (40e49, 50e59, 60e69 or 70 years) and
calendar period (2005e2006, 2007e2009 or 2010e2012).
Follow-up time was calculated from the index date until
the diagnosis date of any first cancer (except for non-
melanoma skin cancer), death or end of follow-up,
whichever occurred first, taking into account changes
in the age categories and calendar periods [30]. Analyses
stratified by age at first dispensed prescription (<60,
60e69 and 70 years) were based on the recommended
age for MHT induction (<60 years) and cessation (70
years) [31e34]. Score tests for trend were used to assess
linear effects of age on the risk of cancer. To assess the
influence of MHT type (E-MHT and EP-MHT) on
cancer risk, a regression with interaction term was fitted
and Wald test was used to test the statistical significance
(alpha Z 0.05). Additional analyses evaluated specific
oestrogen formulation for only E-MHT use, progestinTable 1
Characteristics of all women (40 years) prescribed systemic menopausal h
2012.
Characteristics Ever-users of MHT Ever-users of oestrog
Numbers (%) Numbers (%)
Total 290,186 (100.0) 135,988 (46.9)
Age at first prescription
40e49 years 46,299 (16.0) 14,196 (10.4)
50e59 years 127,773 (44.0) 43,385 (31.9)
60e69 years 59,592 (20.5) 28,887 (21.2)
70 years 56,522 (19.5) 49,520 (36.4)
Year of first prescription
2005e2006 208,555 (71.9) 100,090 (73.6)
2007e2009 46,736 (16.1) 20,553 (15.1)
2010e2012 34,895 (12.0) 15,345 (11.3)
This table is based on the Swedish Prescribed Drug Registry.regimen and type for EP-MHT, and duration. Duration
of use was categorised into <1, 1e2, 3e4 and 5 years.
Sensitivity analyses excluded the first calendar period
(2005e2006) comparing E-MHT and EP-MHT. Ana-
lyses were performed with STATA 14.2 (StataCorp,
Texas, USA) and Microsoft Excel 14.4.0 (Microsoft
Corporation).3. Results
3.1. Participants
Of all 290,186 MHT ever-users, 135,988 (47%) used E-
MHT and 154,198 (53%) used EP-MHT (Table 1). This
corresponds to 7.3% of all Swedish women of 40 years or
above using MHT in 2005, and up to 12.3% among
women aged between 50 and 59 years (Table 1). The
majority of MHT ever-users (60%) were younger than
60 years at enrolment. E-MHT users were on average
older than EP-MHT users, and median follow-up time
was 7 years. The 16 pre-defined cancer sites comprised the
majority (81%) of all incident cancers amongMHT users.
3.2. All cancer
The risk of any cancer was 9% increased among MHT
ever-users (SIR Z 1.09, 95% CI: 1.07e1.11; Table 2).
The SIR was lower among E-MHT users (SIR Z 1.04,
95% CI: 1.01e1.06) than that of EP-MHT users
(SIR Z 1.14, 95% CI: 1.12e1.17). For EP-MHT users,
the risk increased with age (SIRZ 1.3, 95% CI: 1.3e1.4,
women 70 years).
Of specific oestrogen formulations among E-MHT
users, the risk was marginally increased for oestradiol
(SIRZ 1.04, 95% CI: 1.00e1.08) and higher for tibolone
use (SIR Z 1.14, 95% CI: 1.08e1.21; Table 3). Contin-
uous EP-MHT regimen was followed by 18% increased
risk (SIRZ 1.18, 95% CI: 1.15e1.21), but no association
was found for sequential EP-MHT (Table 3).ormone therapy (MHT) in Sweden between July 2005 and December
en MHT Ever-users of oestrogen
plus progestin MHT
Proportion using











The overall risk of cancer following systemic menopausal hormone therapy (MHT) use by MHT regimen and age at first prescription, expressed









All women <60 years 60e69 years 70 years
All incident cancers
All MHT 16,813 (5.8) 1.09 (1.07e1.11) 1.08 (1.05e1.12) 1.09 (1.06e1.11) 1.10 (1.07e1.13) 0.000 <0.001
Oestrogen-only MHT 8131 (6.0) 1.04 (1.01e1.06) 1.07 (1.01e1.13) 1.04 (1.00e1.08) 1.02 (0.99e1.06) 0.000
Oestrogen plus progestin MHT 8682 (5.6) 1.14 (1.12e1.17) 1.09 (1.05e1.13) 1.04 (1.01e1.08) 1.33 (1.26e1.40) 0.000
Main female reproductive organ cancers (Breast, endometrium and ovarian)
All MHT 8160 (2.8) 1.31 (1.28e1.34) 1.00 (0.96e1.04) 1.48 (1.43e1.53) 1.57 (1.50e1.64) 0.000 <0.001
Oestrogen-only MHT 3452 (2.5) 1.20 (1.16e1.24) 0.93 (0.86e1.00) 1.23 (1.16e1.31) 1.35 (1.28e1.43) 0.000
Oestrogen plus progestin MHT 4708 (3.1) 1.41 (1.37e1.45) 1.03 (0.98e1.09) 1.65 (1.58e1.73) 2.25 (2.08e2.42) 0.000
All gastrointestinal tract cancers (OesophagusDcardia, liver, gall and bile duct, pancreas, gut, colon and rectum)
All MHT 2436 (0.8) 0.90 (0.86e0.94) 0.97 (0.89e1.07) 0.90 (0.84e0.96) 0.87 (0.82e0.92) 0.000 <0.001
Oestrogen-only MHT 1399 (1.0) 0.91 (0.86e0.96) 1.02 (0.86e1.20) 0.95 (0.86e1.05) 0.88 (0.82e0.94) 0.000
Oestrogen plus progestin MHT 1037 (0.7) 0.88 (0.83e0.94) 0.93 (0.85e1.06) 0.86 (0.78e0.94) 0.84 (0.73e0.95) 0.000
This table is based on the Swedish Prescribed Drug Registry, Cancer Registry and Death Registry and Registry of the Total Population for the
background population.
a Age was modelled categorically to assess linear trend over age categories.
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The overall risk of the main female reproductive organ
(invasive breast, endometrial or ovarian) cancers is
presented in Table 2. The risk was increased for both E-
MHT and EP-MHT, but more strongly for EP-MHT
users (SIR Z 1.4, 95% CI: 1.4e1.5).
The overall risk of specifically invasive breast cancer is
presented in Table 4. The magnitude of risk was stronger
in EP-MHT users (SIRZ 1.4, 95% CI: 1.4e1.5) than in
E-MHT users (SIRZ 1.05, 95% CI: 1.01e1.10), and for
EP-MHT users, the risk increased with age at first pre-
scription (SIR Z 2.2, 95% CI: 2.0e2.4 among women
70 years). Of specific oestrogen formulations, oestradiol
and tibolone increased the risk, whereas oestriol was
instead associated with a reduced risk (SIRZ 0.85, 95%
CI: 0.79e0.92; Table 3). Both EP-MHT regimens
(continuous and sequential) increased the risk, but
continuous EP-MHT regimen was followed by a higher
risk (SIRZ 1.6, 95% CI: 1.5e1.6; Table 3).
The risk of endometrial cancer was 12% increased for
MHT ever-users (SIRZ 1.12, 95% CI: 1.06e1.19; Table
4). However, the increased risk was limited to women
aged 70 years (SIR Z 1.8, 95% CI: 1.6e1.9). Of the
oestrogen formulations, oestradiol reduced the risk
(SIR Z 0.2, 95% CI: 0.2e0.3), whereas oestriol and
tibolone increased the risk (Table 3). Continuous EP-
MHT regimen reduced the risk by 28%, but not
sequential EP-MHT (Table 3).
The risk of ovarian cancer wasmarginally increased for
MHT ever-users, and more strongly for women aged70
years (SIRZ 1.2, 95%CI: 1.0e1.4; Table 4). No evidence
was found that SIRs varied by oestrogen formulations
(Table 3). Both progesterone- and testosterone-derivedEP-MHT marginally increased the risk by about 20%
(Table 3).
3.4. Gastrointestinal cancers
MHT ever-use was associated with a 10% decreased risk
of gastrointestinal cancers (SIR Z 0.90, 95% CI:
0.86e0.94; Table 2). In separate analyses, statistically
significant decreased risk estimates were found for
oesophageal (SIR Z 0.8), liver (SIR Z 0.8) and colon
cancer (SIR Z 0.9; Table 5). Of the oestrogen formu-
lations, both oestradiol and oestriol reduced the risk of
all gastrointestinal cancers by 11%, and all oestrogen
formulations reduced the risk of colon cancer over 60%
(Table 3). Continuous EP-MHT regimen reduced the
risk of gastrointestinal cancers, but sequential EP-MHT
did not (Table 3).
3.5. Other cancers
The risk of lung cancer is presented in eTable 2. The
overall SIR was increased among EP-MHT users
(SIR Z 1.14, 95% CI: 1.05e1.23), but not among E-
MHT users. The SIR was increased among women <60
years (both MHT types), and the highest SIR was found
among EP-MHT users 70 years (SIR Z 1.6, 95% CI:
1.4e1.9).
The SIR for malignant melanoma was 19%
(SIR Z 1.2, 95% CI: 1.1e1.3) increased among MHT
ever-users, and MHT type did not change the associa-
tion (eTable 2). The SIR was especially increased among
MHT users aged between 60 and 69 years (SIR Z 1.3,
95% CI: 1.2e1.4), and similar associations were found
for both MHT types.
Table 3
The risk of cancer following systemic menopausal hormone therapy (MHT) use by oestrogen formulation, progestin type and regimen and age at first prescription, expressed as standardised incidence
ratios (SIRs) and 95% confidence intervals (CIs).a
Subgroups Total number of exposed
individuals (%)
All cancers All gastrointestinal
cancers
Breast cancer Ovarian cancer Endometrial cancer Colon cancer
Total number of cases in exposed 16,813 2436 6376 573 1211 1106
Only oestrogen formulation
Oestradiol 53,339 (39.2) 1.04 (1.00e1.08) 0.89 (0.80e0.99) 1.14 (1.08e1.22) 0.91 (0.72e1.13) 0.23 (0.16e0.31) 0.29 (0.24e0.35)
Oestriol 55,653 (40.9) 1.01 (0.98e1.05) 0.89 (0.83e0.96) 0.85 (0.79e0.92) 1.14 (0.93e1.37) 1.92 (1.75e2.11) 0.32 (0.28e0.37)
Tibolone 17,992 (13.2) 1.14 (1.08e1.21) 1.00 (0.85e1.18) 1.36 (1.23e1.49) 0.94 (0.64e1.33) 1.51 (1.23e1.84) 0.38 (0.29e0.50)
Oestrogen plus progestin therapy
Progestin regimen
Only continuous combinations 92,381 (59.9) 1.18 (1.15e1.21) 0.91 (0.85e0.98) 1.57 (1.51e1.63) 1.06 (0.91e1.22) 0.72 (0.63e0.82) 0.90 (0.81e1.01)
Only sequential combinations 28,263 (18.3) 1.03 (0.96e1.10) 0.86 (0.69e1.05) 1.13 (1.02e1.25) 1.24 (0.88e1.70) 1.14 (0.87e1.47) 0.74 (0.51e1.04)
Progestin type
Only progesterone derived 47,308 (30.7) 1.14 (1.10e1.19) 0.81 (0.72e0.91) 1.41 (1.33e1.49) 1.23 (1.00e1.50) 1.35 (1.17e1.54) 0.88 (0.74e1.04)
Only testosterone derived 85,659 (55.6) 1.19 (1.16e1.22) 0.96 (0.88e1.04) 1.52 (1.46e1.59) 1.20 (1.02e1.39) 0.87 (0.76e0.99) 0.91 (0.80e1.03)
Progestin regimen and type
Progesterone-derived continuous 30,123 (19.5) 1.12 (1.07e1.17) 0.87 (0.75e0.99) 1.49 (1.39e1.60) 1.09 (0.83e1.41) 0.63 (0.48e0.80) 0.86 (0.69e1.06)
Testosterone-derived continuous 53,360 (34.6) 1.24 (1.20e1.28) 0.96 (0.87e0.98) 1.70 (1.62e1.78) 1.10 (0.91e1.33) 0.74 (0.63e0.87) 0.93 (0.81e1.07)
Progesterone-derived sequential 3341 (2.2) 1.09 (0.91e1.29) 0.48 (0.21e0.95) 1.25 (0.95e1.60) 1.78 (0.77e3.51) 1.81 (0.99e3.04) 0.73 (0.24e1.70)
Testosterone-derived sequential 21,247 (13.8) 1.05 (0.97e1.13) 0.97 (0.76e1.21) 1.17 (1.04e1.31) 1.24 (0.82e1.79) 0.85 (0.58e1.20) 0.79 (0.51e1.16)
This table is based on the Swedish Prescribed Drug Registry, Cancer Registry and Death Registry and Registry of the Total Population for the background population.











































The risk of the main female reproductive organ cancers following systemic menopausal hormone therapy (MHT) use by MHT regimen and age at
first prescription, expressed standardised incidence ratios (SIRs) and 95% confidence intervals (CIs).
Subgroups Number of
observed cases (%)




All women <60 years 60e69 years 70 years
Breast cancer
All MHT 6376 (2.2) 1.24 (1.21e1.27) 1.13 (1.08e1.18) 1.32 (1.27e1.37) 1.28 (1.21e1.35) 0.000 <0.001
Oestrogen only 2548 (1.9) 1.05 (1.01e1.10) 1.09 (1.00e1.18) 1.09 (1.02e1.16) 1.00 (0.93e1.07) 0.136
Oestrogen plus progestin 3828 (2.5) 1.40 (1.36e1.45) 1.15 (1.09e1.21) 1.48 (1.41e1.55) 2.19 (2.01e2.37) 0.000
Endometrial cancer
All MHT 1211 (0.4) 1.12 (1.06e1.19) 0.79 (0.68e0.91) 0.83 (0.75e0.92) 1.75 (1.61e1.90) 0.000 0.710
Oestrogen only 646 (0.5) 1.17 (1.08e1.27) 0.44 (0.30e0.62) 0.68 (0.57e0.82) 1.75 (1.59e1.92) 0.000
Oestrogen plus progestin 565 (0.4) 1.07 (0.98e1.17) 0.94 (0.80e1.11) 0.94 (0.82e1.07) 1.78 (1.49e2.11) 0.000
Ovarian cancer
All MHT 573 (0.2) 1.09 (1.00e1.19) 1.13 (0.97e1.31) 0.99 (0.86e1.14) 1.22 (1.03e1.42) 0.000 0.176
Oestrogen only 258 (0.2) 1.03 (0.91e1.17) 1.02 (0.76e1.35) 0.87 (0.69e1.09) 1.18 (0.97e1.41) 0.001
Oestrogen plus progestin 315 (0.2) 1.15 (1.03e1.29) 1.18 (0.98e1.41) 1.08 (0.90e1.28) 1.36 (0.97e1.85) 0.000
This table is based on the Swedish Prescribed Drug Registry, Cancer Registry and Death Registry and Registry of the Total Population for the
background population.
a Age was modelled categorically to assess linear trend over age categories.
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tral nervous system or kidneys (eTable 2). The risk of
thyroid cancer was decreased for EP-MHT users
(eTable 2).Table 5
The risk of cancers of the gastrointestinal tract following systemic menopa





All women <60 ye
Oesophageal cancer (Dcardia)
All MHT 86 (0.0) 0.81 (0.64e1.00) 0.53 (0.
Oestrogen-only MHT 50 (0.0) 0.88 (0.65e1.16) 0.34 (0.
Oestrogen plus progestin MHT 36 (0.0) 0.72 (0.50e1.02) 0.62 (0.
Gastric cancer
All MHT 149 (0.1) 0.89 (0.75e1.05) 1.21 (0.
Oestrogen-only MHT 83 (0.1) 0.84 (0.66e1.05) 0.73 (0.
Oestrogen plus progestin MHT 66 (0.0) 0.96 (0.74e1.22) 1.42 (0.
Pancreas cancer
All MHT 311 (0.1) 0.94 (0.84e1.05) 1.03 (0.
Oestrogen-only MHT 177 (0.1) 0.99 (0.84e1.15) 1.43 (0.
Oestrogen plus progestin MHT 134 (0.1) 0.89 (0.74e1.05) 0.84 (0.
Gallbladder and bile duct cancer
All MHT 129 (0.0) 0.88 (0.73e1.05) 1.23 (0.
Oestrogen-only MHT 77 (0.1) 0.91 (0.71e1.15) 1.25 (0.
Oestrogen plus progestin MHT 52 (0.0) 0.85 (0.63e1.11) 1.22 (0.
Liver cancer
All MHT 94 (0.0) 0.81 (0.65e0.99) 1.12 (0.
Oestrogen-only MHT 49 (0.0) 0.77 (0.56e1.02) 1.29 (0.
Oestrogen plus progestin MHT 45 (0.0) 0.86 (0.63e1.16) 1.04 (0.
Colon cancer
All MHT 1106 (0.38) 0.90 (0.84e0.95) 0.90 (0.
Oestrogen-only MHT 660 (0.5) 0.91 (0.84e0.99) 0.91 (0.
Oestrogen plus progestin MHT 446 (0.3) 0.88 (0.80e0.97) 0.90 (0.
Rectal cancer
All MHT 561 (0.2) 0.92 (0.84e1.00) 0.99 (0.
Oestrogen-only MHT 303 (0.2 0.99 (0.83e1.05) 1.08 (0.
Oestrogen plus progestin MHT 258 (0.2) 0.90 (0.79e1.02) 0.96 (0.
This table is based on the Swedish Prescribed Drug Registry, Cancer Regi
background population.
a Age was modelled categorically to assess linear trend over age categori3.6. Sensitivity analysis
Duration of MHT use was estimated after exclusion of






ars 60e69 years 70 years
25e0.97) 0.75 (0.51e1.08) 0.99 (0.71e1.34) 0.000 0.469
04e1.21) 0.83 (0.46e1.40) 1.00 (0.68e1.41) 0.000
27e1.21) 0.69 (0.40e1.13) 0.94 (0.43e1.79) 0.034
85e1.67) 0.81 (0.58e1.10) 0.82 (0.63e1.04) 0.000 0.069
29e1.51) 0.67 (0.36e1.12) 0.91 (0.69e1.19) 0.000
97e2.05) 0.91 (0.59e1.33) 0.50 (0.23e0.94) 0.009
78e1.33) 0.87 (0.72e1.04) 0.98 (0.81e1.18) 0.000 <0.001
93e2.12) 0.98 (0.74e1.27) 0.91 (0.72e1.21) 0.002
57e1.18) 0.78 (0.60e1.00) 1.24 (0.86e1.72) 0.000
81e1.77) 0.72 (0.50e0.99) 0.89 (0.67e1.15) 0.000 0.620
60e2.37) 0.75 (0.43e1.22) 0.93 (0.68e1.24) 0.000
73e1.90) 0.69 (0.42e1.06) 0.76 (0.38e1.36) 0.000
72e1.65) 0.81 (0.56e1.11) 0.67 (0.45e0.95) 0.000 0.245
59e2.45) 0.80 (0.45e1.32) 0.65 (0.41e0.97) 0.014
59e1.67) 0.81 (0.50e1.24) 0.74 (0.32e1.46) 0.000
77e1.05) 0.94 (0.85e1.04) 0.87 (0.80e0.95) 0.000 0.001
68e1.19) 0.97 (0.83e1.14) 0.89 (0.80e0.98) 0.000
74e1.08) 0.92 (0.0e1.05) 0.80 (0.66e0.97) 0.000
83e1.17) 0.96 (0.83e1.10) 0.84 (0.72e0.97) 0.0000 0.002
79e1.43) 1.06 (0.86e1.30) 0.83 (0.70e0.98) 0.0000
77e1.17) 0.88 (0.72e1.06) 0.85 (0.62e1.15) 0.0000
stry and Death Registry and Registry of the Total Population for the
es.
J. Simin et al. / European Journal of Cancer 84 (2017) 60e6866women used MHT for less than 1 year (eTable 3). The
risk of all cancer and risk of each cancer type analysed
was similar for all duration groups. The exclusion of the
first calendar period (2005e2006) did not change the
direction of the associations, although the 95% CIs were
wider due to smaller sample sizes (eTable 4).
4. Discussion
This study reveals a slightly increased risk of cancer
overall among women with ever-use of systemic MHT.
The risk of invasive breast, endometrium and ovary
cancer was particularly increased, whereas the risk of
gastrointestinal cancers was decreased. The risk esti-
mates were, however, dependent on MHT type,
formulation and regimen. For the different oestrogen-
only formulations, the risk of any cancer was non-
existent for oestriol, minimal for oestradiol and more
substantial for tibolone. For progestin regimens, the
excess risk of any cancer was higher for continuous EP-
MHT use, but not for sequential use of progestin, and
the risk appeared to be higher for testosterone-derived
regimens than progesterone-derived regimens.
The main strength of the present study is the inclu-
sion of a large number of systemic MHT ever-users with
variation in regimens, ascertained through dispensed
prescriptions. The use of high-quality health data from
nationwide registries provides virtually complete ascer-
tainment of systemic MHT use (not available over-the-
counter) and cancer outcomes, feasible only in a few
countries globally. Although a relatively high propor-
tion of Swedish women were consuming MHT at the
start of the study period (2005), Sweden became an
“average” consumer compared to other European
countries around 2010 [2]. Since the variety in popu-
larity of MHT use has decreased in Europe (between 3%
and 27% in 2002 to 2e12% in 2010 [2]), prescription
practices probably became more similar in Europe,
resulting in a high external validity of our findings and
generalisability towards other European countries.
Generalisability to other regions may depend on the
preference of the MHT types and formulations used.
The risk of confounding is an important limitation
inherent to the observational study design. The nation-
wide Swedish health data registries do not contain
detailed information about all potential confounding
factors for the entire population. Body mass index, age at
menarche, tobacco smoking, alcohol consumption,
comorbidity and use of oral anti-contra-
ceptivesdrecorded only since 2005dare potential con-
founders for some of the studied cancer types, which
were not possible to control for in this study [35,36].
Because no information was available for MHT use
before July 2005, we lacked information for duration of
use for approximately 60% of the cohort members. To
assess the potential impact of left censoring, we excluded
the first calendar period, limiting the duration of use to amaximum of 5 years. All SIRs remained in the same
direction after this exclusion, indicating robustness of the
findings. Another concern is a risk of selection bias.
Although we included virtually all MHT ever-users in
Sweden (counteracting selection bias), it is less likely that
women at high risk of particularly breast cancer receive
MHT [37]. It is also possible that cancer is diagnosed
earlier in MHT users if they have a higher utilisation of
health care services [38]. This potential lead time and (for
some cancers) over-diagnosis bias could overestimate the
SIRs. Nevertheless, this alone should not explain the
differences on the cancer risk shown by various MHT
regimens such as for invasive breast cancer.
The results for the major cancer types are consistent
with findings from studies examining separate cancer
sites. There is convincing evidence that particularly EP-
MHT increases the risk of breast cancer [5,7]. Our
findings further suggest that the excess risk of invasive
breast cancer increases with age when EP-MHT use is
initiated, whereas the Women’s Health Initiative trial
grouped women aged 50e79 years together [5]. The
SIRs of the present study also had greater precision and
appeared to be consistent across subgroups by age and
MHT type (E-MHT and EP-MHT). The findings for
endometrial cancer need to be interpreted with caution,
because we did not exclude women with no or a reduced
risk, i.e. those having undergone hysterectomy for
benign reasons (i.e. 90% of all hysterectomies) [39]. In
Sweden, approximately 10% of all women undergo
hysterectomy during their lifetime [35]. Among the
oestrogen-only users, who should not have an intact
uterus according to the MHT recommendations, only
38,912 women (28.6%) underwent hysterectomy for
non-malignant reasons. A sensitivity analysis excluding
these women provided an SIR of 1.14 (95% CI:
1.03e1.26) for endometrial cancer, which is similar to
the presented results. Yet, hysterectomy is likely to be
underreported among older women, because the Patient
Registry was only nationwide complete since 1987.
Among women aged <60, 60e69 and 70 years at first
prescription, 37%, 40% and 15% had a recorded hys-
terectomy in this cohort, respectively,ddespite the ex-
pected decrease in popularity over time [35,36]. Thus,
these results suggest that systemic E-MHT is still pre-
scribed among women with an intact uterus despite the
current recommendations. Another interesting finding
conflicting with the current recommendations is the
relatively large proportion of women above 70 years of
age (5.9%) using MHT. Yet, previous studies showed
that up to 10e20% have frequent vasomotor symptoms
beyond the age of 70 years, and a study on MHT use
among Swedish octogenarians has even suggested new
MHT initiation at this older age [40,41]. In this group,
MHT was primarily prescribed by general practitioners
(37%) and gynaecologists (31%) but the indication of use
is unfortunately not recorded in the Swedish Drug
Registry [40].
J. Simin et al. / European Journal of Cancer 84 (2017) 60e68 67This study also indicates that MHT reduces the risk
of gastrointestinal cancer, with the most pronounced
associations for oesophageal, liver and colon cancers;
which were also consistent with a more in-depth analysis
of our group showing reduced risks of both major his-
tological subtypes of oesophageal cancer (adenocarci-
noma and squamous cell carcinoma) [42] For other
cancers, evidence is less clear, and there may be differ-
ences by histological subtype which were not explored
further in the present study. A slightly increased risk of
lung cancer was observed, which may indicate con-
founding by smoking.
This study has shown that MHT mainly increases the
risk of female reproductive organ cancers. Assuming
causality, this study suggests an estimated 8.3% (attrib-
utable fraction) of the cancers among MHT users, and
1.1% (population attributable fraction) among all
women in Sweden could be attributed to MHT use.
Compared to other risk factors, such as tobacco smok-
ing, this attributable fraction is 30 times smaller [43,44].
Relating these to numbers, it translates to 212 excess
cancers per 100,000 person-years, 159 excess female
reproductive organ cancers and 2 less gastrointestinal
cancers per 100,000 person-years, among MHT ever-
users. Because these data also suggest that MHT re-
duces the risk of gastrointestinal cancer, a less restrictive
approach in clinical care might be considered, in
particular for women with substantial menopause-
related symptoms. However, studies with longer
follow-up are needed to assess the safety of different
MHT formulations.
Although the overall risk of cancer was lower for E-
MHT than EP-MHT, these results were not consistent
for all cancer types.
In conclusion, this large cohort study indicates a
slight increase of overall cancer among MHT users. The
increased risk of cancer of female reproductive organs is
partly balanced by a decreased risk of gastrointestinal
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